Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. SPY
2. PATH
3. KBH
4. AZO
5. USO
6. QQQ
7. ORCL
8. RCL
9. ONON
10. PLTR

Go back to Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1150.99 -19.15 (1.64%)
Previous Close $1170.14    52 Week High $88.16 
Open $1174.71    52 Week Low $67.88 
Day High $1188.88    P/E 266.43 
Day Low $1145.98    EPS $4.32 
Volume 2,117,608